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Abstract
Background: Follow-up care provided via telemedicine (TM) is intended to be a more integrated care pathway to manage
diabetes-related foot ulcers (DFU) than traditionally-delivered healthcare. However, knowledge of the effect of TM follow-up
on PROMs including self-reported health, well-being and QOL in patients with DFUs is lacking and often neglected in RCT
reports in general. Therefore, in this study of secondary outcomes from the DiaFOTo trial, the aim was to compare changes
in self-reported health, well-being and QOL between patients with DFUs receiving telemedicine follow-up care in primary
healthcare in collaboration with specialist healthcare, and patients receiving standard outpatient care.
Methods: The current study reports secondary endpoints from a cluster randomized controlled trial whose primary
endpoint was ulcer healing time. The trial included 182 adults with diabetes-related foot ulcers (94/88 in the
telemedicine/standard care groups) in 42 municipalities/districts, recruited from three clinical sites in Western Norway.
Mean (SD) diabetes duration for the study population was 20.8 (15.0). The intervention group received care in the
community in collaboration with specialist healthcare using an asynchronous telemedicine intervention. The
intervention included an interactive web-based ulcer record and a mobile phone enabling counseling and
communication between the community nurses and specialist healthcare; the control group received standard
outpatient care. In total 156 participants (78/78) reported on secondary endpoints: self-reported health, well-being and
quality of life evaluated by generic and disease-specific patient-reported outcome measures (e.g. Euro-QOL, the
Hospital Anxiety and Depression Scale (HADS), Problem Areas in Diabetes (PAID), Neuropathy and Foot Ulcer–Specific
Quality of Life Instrument (NeuroQOL)). Linear mixed-effects regression was used to investigate possible differences in
changes in the scores between the intervention and control group at the end of follow-up.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: miv@hvl.no
1Faculty of Health and Social Sciences, Department of Health and Caring
Sciences, Western Norway University of Applied Sciences, N-5020 Bergen,
Norway
2Department of Medicine, Section of Endocrinology, Stavanger University
Hospital, Stavanger, Norway
Full list of author information is available at the end of the article
Iversen et al. BMC Endocrine Disorders          (2020) 20:157 
https://doi.org/10.1186/s12902-020-00637-x
(Continued from previous page)
Results: In intention to treat analyses, differences between treatment groups were small and non-significant for the
health and well-being scale scores, as well as for diabetes-related distress and foot ulcer-specific quality of life.
Conclusions: There were no significant differences in changes in scores for the patient reported outcomes between
the intervention and control group, indicating that the intervention did not affect the participants’ health, well-being
and quality of life.
Trial registration: Clinicaltrials.gov, NCT01710774. Registered October 19th, 2012.
Keywords: Diabetic foot, Psychological aspects, Health care delivery, Clinical trials
Background
Follow-up care provided via telemedicine (TM) is
intended to be a more integrated care pathway to man-
age diabetes-related foot ulcers (DFU) than traditionally-
delivered healthcare. However, TM follow-up in diabetes
care can alter patient-provider relationships, and might
have unintended negative effects on health, well-being
and quality of life (QOL) [1]. Hence, it is important to
also evaluate self-reported health and well-being out-
comes among those receiving telemedicine follow-up
care. Measures of health-related quality of life (HRQOL)
among adults living with diabetes-related foot ulcers
have shown that the occurrence of a DFU, in general, is
associated with reduced quality of life [2–4]. While sev-
eral different patient-reported outcome measures
(PROMs) have been used, none has been found to be
more appropriate than others in assessing HRQOL asso-
ciated with diabetes-related foot ulcers [3, 4]. Although
generic measures such as the WHO-Five Well-Being
Index (WHO-5) and the Euro-QOL five-dimension ques-
tionnaire (EQ-5D-5L) are useful, they do not capture
disease-specific aspects of HRQOL [4]. Disease or condi-
tion specific PROMs, such as Problem Areas in Diabetes
(PAID) and Neuropathy and Foot Ulcer–Specific Quality
of Life (NeuroQOL) may be more useful to study foot
ulcer patients’ distress and their response to treatment [5].
Moreover, identifying emotional distress in foot ulcer pa-
tients with diabetes is important as depression is associ-
ated with development of the first foot ulcer [6] and
symptoms of depression are associated with an increased
risk of a diabetes-related foot ulcer in a dose response
manner [7]. Analyses of PROMs utilizing validated instru-
ments allow healthcare providers to determine whether
different treatments provide patients with the best pos-
sible outcomes and improve HRQOL [4].
Two TM randomized controlled trials among
adults with a DFU have been performed, one in
Denmark [8] and one in Norway [9]. Both studies
evaluated the effect of TM on ulcer healing, ampu-
tation and death and compared TM with SOC.
The Danish study found no significant differences
regarding amputation and healing time [8]. In the
Norwegian study, the Diabetic Foot and Telemedi-
cal Images Project (DiaFOTo) [9], we confirmed
the hypothesis that TM in patients with DFUs in pri-
mary healthcare, in collaboration with specialist health-
care, was non-inferior to standard outpatient care (SOC)
regarding healing time among those whose DFU healed
(79.8% vs 76.1%). The direction of the effect estimates for
healing time in months (0.43 (− 1.50, 0.65)), death (− 0.4%
(− 6.5, 5.7%)), and consultations all favored TM, although
there were no statistically significant effects. Telemedicine
monitoring was superior regarding avoidance of amputa-
tions (6.4% vs 14.8%) in the Norwegian study. However,
knowledge of the effect of TM follow-up on PROMs (in-
cluding self-reported health, well-being and QOL) in pa-
tients with DFUs is lacking and often neglected in RCT
reports in general. Therefore, in this study of secondary
outcomes from the DiaFOTo trial, the aim was to com-
pare changes in self-reported health, well-being and QOL
between patients with DFUs receiving telemedicine
follow-up care in primary healthcare in collaboration with
specialist healthcare, and patients receiving SOC.
Methods
Trial design
The design of the study has been described previously
[9, 10]. Briefly, this was a multicenter cluster-
randomized controlled noninferiority trial. Patients from
three clinical sites in western Norway were included
(NCT01710774). The recruitment period lasted from
September 2012 to June 2016. A total of 182 patients
were included, 94 in the TM group and 88 in the control
group in 42 municipalities/districts. Forty-two clusters
were matched in 21 pairs which were then randomized
to either TM or control. These were matched in pairs
according to population size and rural/urban character-
istics. The randomization sequences were generated by
an independent statistician using SPSS version 21 statis-
tical software (IBM Corp) [10]. The study was approved
by the Western Norway Regional Committee for Med-
ical and Health Research Ethics (2011/1609). All partici-
pants gave written consent. The study adheres to
CONSORT guidelines (Additional file 1).
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Participants
Included in the original trial were patients with type 1 or
type 2 diabetes who were 20 years or older, diagnosed with
a new DFU [9], defined as a skin lesion below the ankle.
Excluded were patients who had an ulcer on the same foot
treated during the last 6months in specialist healthcare or
a diagnosis of mental disorder or cognitive impairment.
Another exclusion criteria was having a life expectancy
less than 1 year, and the patient also had to be able to
understand and write Norwegian [10]. Patients in both
groups were followed until ulcer healing, amputation, or
death, up to a maximum of 12months of follow-up. (The
Consort flow chart for the primary study is available as
Fig. S1 in the supplementary appendix.)
In the current study we included all participants with at
least one valid patient-reported outcome measure at base-
line in the TM group (n = 78 (83.0%)) and in the control
group (n = 78 (88.6%)). PROMs were collected at baseline
and at predefined endpoints (healed ulcer or amputation
or at 12months if the ulcer did not heal). For persons
who died during follow-up or were lost to follow-up for
other reasons, only the baseline measurements were used
in analyses and these persons did thus not contribute to
the estimation of the intervention effect.
Intervention
Telemedicine (TM)
The randomization procedures and a more in-depth de-
scription of the intervention have been reported previ-
ously [9]. Briefly, community nurses used a mobile
phone to take pictures of the ulcer which was then sent
via a web-based platform to the hospital for review by a
specialist health care professional, facilitating counseling
and feed-back. This platform is a web-based ulcer record
system accessible from mobile devices and computers
via the Internet [9–11]. The platform facilitate to register
clinical data regarding the ulcers, digital images of the
ulcers, a written assessment of the ulcer, and to ask for
and give guidance. Measurements can be compared over
time to visualize the healing process of the ulcer. This
allows all involved staff to contribute, even though they
are on a distance. This system is customized for collab-
oration, discussions, and advice regarding the treatment
between cooperating medical staff in different health
care institutions. The main reason for using the web-
based ulcer record system is the collaboration function-
ality that enables integrated care across different levels
of the health care sector. Relevant ulcer data are access-
ible to the involved staff, regardless of employment in
community care or specialist health care. During follow-
up, the community nurses provided care under supervi-
sion of the specialist nurses at the outpatient clinics and
communicated at least weekly with the specialist nurses
at the outpatient clinic [10].
Standard outpatient care
Patients in the control group received standard care pro-
vided by the outpatient clinic, normally scheduled to
take place every second week. The medical treatment
given to the control and intervention group is based on
the same evidence-based procedures [10].
PROMs
We used both generic and disease-specific PROMs to as-
sess the patients’ perceptions of the intervention on self-
reported health and well-being, and QOL. Included were
three generic instruments (Euro-QOL EQ-5D-5L/ EQ-
5D-VAS, the Hospital Anxiety and Depression Scale
(HADS), the WHO-Five Well-Being Index (WHO-5)),
and two disease-specific measures; Problem Areas In
Diabetes (PAID-20) and Neuropathy and Foot Ulcer–
Specific Quality of Life (NeuroQOL).
We used the EQ-5D-5L questionnaire as a health utility
score [12]. Part one comprises five single items: mobility,
self-care, usual activities, pain/discomfort and anxiety/de-
pression (dimensions of health) with ratings on five levels of
perceived problems from no problems (1) to extreme prob-
lems (5). The level scores are presented as global health indi-
ces with a weighted total value for health status [13]. The
second part is a Visual Analogue Scale (VAS) ranging from 0
(worst health state) to 100 (best health state), and used as an
overall measure of perceived health status [12]. The WHO-5
was used to describe well-being during the previous 2weeks
[14]. Five items with ratings from 0 to 5. Item scores are
summed (0–25) and transformed to a 0–100 scale with
higher scores indicating better well-being. The HADS
assessed anxiety and depressive symptoms during the past
week [15]. This instrument comprises seven items on anxiety
(HADS-A) and seven items on depression (HADS-D). Each
item is scored from 0 to 3, yielding a maximum score of 21.
Higher scores indicate a higher symptom load.
Diabetes distress was measured with PAID-20 [16, 17].
The instrument covers frequently reported emotional states.
Scale scores are transformed to a 0–100 scale, with 100 indi-
cating greater distress. The cut-off score is suggested to be
equal or more than 40. The NeuroQOL assessed patients’
perception of the impact of foot ulcers on their QOL [18].
The instrument consists of six domains: 1) painfully symp-
toms and paresthesia; 2) symptoms of reduced/lost feeling in
the feet; 3) diffuse sensory motor symptoms; 4) restrictions
in daily activities; 5) interpersonal problems and 6) emotional
burden. Higher scores indicate a greater negative impact of
foot ulcers on QOL.
Other measures
Healing of the ulcer was defined as healing (intact skin)
of the whole foot without minor or major amputations.
Amputation was defined as minor or major amputation
before ulcer healing. Amputation performed below the
Iversen et al. BMC Endocrine Disorders          (2020) 20:157 Page 3 of 8
ankle was defined as minor amputation, whereas ampu-
tation above the ankle was defined as major amputation.
Death was defined as death before ulcer healing.
In addition, clinical data, comorbidities and foot ulcer
specific data were collected from the electronic medical
journals at the clinical sites. Those with grade 2 or grade 3
combined with stage C and D were defined as high sever-
ity and all other grades and stages were combined to a
group with versus low and medium severity [19]. Other
measures as demographic data and lifestyle characteristics
were self-reported by the patient [10] (Table 1).
Statistical analyses
Data were analyzed according to the initial group alloca-
tion (intention to treat). Continuous variables are pre-
sented as mean and standard deviations (SD), and
categorical variables are presented as proportions. We
used linear mixed effects regression analyses with random
intercept to account for clustering within treatment
groups. Intra-cluster correlation for the primary outcome
healing time in the main study was 0.0014. All models
were specified with the sum score of the PROMs (EQ-5D-
5L, HADS, WHO-5, PAID-20 and the NeuroQOL sub-
scales respectively) as dependent variables with fixed ef-
fects for time, group allocation and interaction between
time and allocation group. The coefficient for the inter-
action term between time and allocation group was re-
ported as the intervention effect and can be interpreted as
the difference in change in PROM score between the two
groups after adjustment for baseline differences in PROM
score. The intervention effects are reported as regression
coefficients with 95% CIs. For analyses of the dichotomous
outcome PAID> 40 we used generalized estimation equa-
tions (GEE) instead of linear mixed models. Sample size
calculation was reported previously [9].
Additional analyses
In additional analyses, we tested whether distance to the
outpatient clinic moderated the intervention effect. We
conducted a subgroup analysis with a linear mixed
model, including only patients who lived 25 km from the
outpatient clinic. All analyses were also repeated exclud-
ing 13 patients originally assigned to the TM group who
did not receive TM (per protocol analyses) [9, 10]. A
greater percentage of participants in the intervention
group with ulcers on the toes than in the control group
suggested possible differential selection. In sensitivity
analyses we therefore repeated the linear mixed-effects
regression analyses and GEE adjusted for localization of
ulcer. We also did analyses with stratification on severity
of ulcer measured in terms of grade and stage from the
UT classification system [10, 20]. Statistical significance
was defined as P < 0.05. Statistical analyses and graphs
were performed and constructed in Stata (version 14).
Results
Trial participants
In total, 345 patients were assessed for eligibility be-
tween September 2012 and June 2016; of these 163 did
not meet the inclusion criteria. In total 182 patients were
included (94 in the TM group) and 88 in the SOC
group) (Table 1). Most participants were male (73.7%),
the mean HbA1c was 7.9% (SD 1.7), and the majority
used insulin (65.2%). A history of cardiovascular disease
and neuropathy was present in 27.3 and 70.0% of pa-
tients, respectively. Furthermore, most ulcers were clas-
sified as grade 1 and stage A or B at baseline [9].
Overall, characteristics were well balanced between the
two groups at baseline, except type of diabetes and
localization of ulcer. Completion rates for PROMs for
patients with at least one valid PROM at baseline were
87% (Table S1 in the supplementary appendix) (n = 156/
182). Mean (SD) time between baseline measurement
and follow-up measurement of PROMs was 4.4 months
(4.1) in the TM group and 4.2 months (3.6) in the SOC
group (Not shown in table). The mean (± SD) scores for
PROMs at baseline and post-intervention and regression
coefficients for the intervention effect are reported in
Table 2. In addition, unweighted scores for the Neuro-
QOL at baseline and follow-up are reported in Table S2.
Outcome measures
The mean scores for generic measures (EQ-5D-5L,
WHO-5, HADS) were relatively stable from baseline to
post intervention in both treatment groups, with no sig-
nificant intervention effect (Table 2). Within the stand-
ard treatment group, the mean EQ-5D-VAS score
improved slightly (from 57.7 (SD 20.8) to 63.5 (SD 21.4),
P = 0.02) but not in the TM group (from 59.0 (SD 21.8)
to 60.4 (SD 21.7), P = 0.53).
Both disease-specific measures, PAID-20 and Neuro-
QOL, were also relatively stable and did not show an
intervention effect (Table 1). Within the treatment
groups, the mean PAID score increased from baseline
to post intervention in the TM group (P = 0.04), indi-
cating emotional problems. The proportion of patients
with a PAID score of 40 or more decreased from
20.6% at baseline to 17.2% in the TM group (ns) and
increased from 12.9 to 14.6% in the corresponding
time period in the SOC group (ns). The mean
weighted ADL restriction score (subscale from Neuro-
QOL) decreased within the standard treatment group,
indicating less ADL restrictions (from 8.2 (4.4) at
baseline to 6.3 (4.0) at follow-up, P = 0.003), but not
in the TM group (from 7.2 (4.2) at baseline to 6.5
(3.7) at follow-up, P = 0.19) (Table 2). None of the
additional analyses revealed significant differences be-
tween the treatment groups.
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Table 1 Characteristics of the participants: the DiaFOTo study, Western Norwaya
Characteristics Total Telemedicine Standard outpatient care
(n = 156) (n = 78) (n = 78)
Demographic variables
Male sex 115 (73.7) 57 (73.1) 58 (74.4)
Age (years) 65.5 ± 16.3 66.3 ± 16.3 64.7 ± 16.4
Married or Cohabitant 91 (60.7) 42 (56.8) 49 (64.5)
Education levelb
Primary 36 (25.5) 22 (32.4) 14 (19.2)
Secondary 73 (51.8) 34 (50.0) 39 (53.4)
Tertiary 32 (22.7) 12 (17.7) 20 (27.4)
Employed 34 (21.9) 18 (23.4) 16 (20.5)
Travel distance > 25 km to hospital 40 (27.4) 21 (28.4) 19 (26.4)
Lifestyle characteristics
Smoking (yes) 27 (18.1) 14 (18.9) 13 (17.3)
Subgroups of diabetes
Type 1 diabetes 35 (22.4) 11 (14.1) 24 (30.8)
Type 2 diabetes 121 (77.6) 67 (85.9) 54 (69.2)
Diabetes-related variables
Diabetes duration, years 20.8 ± 15.0 19.8 ± 14.1 21.8 ± 15.8
Insulin treatment 101 (65.2) 47 (61.0) 54 (69.2)
HbA1c, (mmol/mol)
c 63 ± 18.6 63 ± 17.5 64 ± 18.6
HbA1c, (%)
b 7.9 ± 1.7 7.9 ± 1.6 8.0 ± 1.7
Ulcer characteristics
Localization of ulcer
Toe 80 (51.3) 49 (62.7) 31 (39.8)
Metatarsal 23 (14.7) 8 (10.3) 15 (19.2)
Heal 12 (7.7) 7 (9.0) 5 (6.4)
Other 41 (26.3) 14 (18.0) 27 (34.6)
Comorbidities
Cardiovascular diseased 42 (27.3) 19 (24.7) 23 (29.9)
Neuropathye 102 (70.0) 51 (70.0) 51 (70.0)
Renal disease, GFR < 60 58 (37.2) 31 (39.7) 27 (34.6)
Retinopathy 53 (37.1) 23 (31.9) 30 (42.3)
Ulcer endpoints
Healing 124 (79.5) 64 (82.1) 60 (76.9)
Amputation 15 (9.6) 4 (5.1) 11 (14.1)
Death 9 (5.8) 4 (5.1) 5 (6.4)
Not healed after 12 months 8 (5.1) 6 (7.8) 2 (2.6)
Data are shown as n (%) Percent of patients with valid values for categorical variables and mean ± SD for continuous variables
aIn the current study we included all participants with at least one valid patient-reported outcome measure at baseline
bEducation level: primary: up to 10 years of compulsory education, secondary: high school or vocational school and tertiary: college/university
cHbA1c measurements were reported using the International Federation of Clinical Chemistry units (mmol/mol) in addition to the derived NGSP units (%) upon
attendance at the outpatient clinic
dCardiovascular disease was defined as a history of angina pectoris, myocardial infarction or stroke
eNeuropathy: Neuropathy was defined as an abnormal pressure sensation evaluated with the 10 g monofilament and/or presence of symptoms and/or signs of
peripheral nerve dysfunction
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Discussion
This is the first randomized controlled trial assessing the
effect of a telemedicine intervention for DFUs, compared
to SOC, designed primarily to study its effect on ulcer
healing. Here we report the effect on self-reported
health, well-being and QOL. PROMs were relatively
stable from baseline to post-intervention in both treat-
ment groups and the intervention did not affect the par-
ticipants’ health, well-being or QOL.
As no previous studies have reported the effect of tele-
medicine follow-up on PROMs in patients with a DFU,
we compare our findings to other relevant telemedicine
studies. Telehealth as implemented in the Whole Systems
Demonstrator Evaluation did not improve QOL or psy-
chological outcomes for patients with chronic obstructive
pulmonary disease (COPD), diabetes, or heart failure over
12months [1]. In a sub-study, for those with COPD there
was a consistent trend of improved health related QOL in
the intention to treat analysis [21]. However, in the sub-
sample of people with diabetes, the telemedicine interven-
tion was not effective [22]. A systematic review including
other studies of patients with COPD found mixed results
on various QOL measures [23]. Another systematic re-
view, on asynchronous and synchronous teleconsultation
for diabetes care, concluded that neither synchronous nor
asynchronous teleconsultations for diabetes care showed
any significant differences between control (usual care)
and intervention groups for QOL. Nevertheless, these
studies found that increased intensity of contact between
provider and patients were perceived as more supportive
and generated more effective communication [24].
Possible mechanisms or pathways by which our telemedi-
cine intervention might have improved PROMs include: (1)
telemedicine might produce better DFU treatment outcomes
(fewer adverse outcomes, quicker recovery time), which in
turn result in better PROMs; and (2) patients might find tele-
medicine more supportive, independent of treatment out-
come. In this study, there was a significantly lower
proportion of amputation the first 12months (n= 6 in TM,
n= 13 in SOC, mean difference− 8.3, 95% CI –16.3, − 0.5%).
DFU treatment outcomes (healing time and patient satisfac-
tion) were similar for the TM and SOC groups. Therefore,
Table 2 Patient-reported outcomes comparing telemedicine versus standard outpatient care: the DiaFOTo study, Western Norwaya
Telemedicine
(n = 78)













Generic Quality of Life measuresc n n n n
EQ-5D-5L, (0–1) 75 0.72 (0.3) 67 0.76 (0.2) 0.06 72 0.70 (0.3) 56 0.75 (0.2) 0.02 −0.01 (−0.08, 0.05) 0.66
EQ-VAS, (0–100) 74 59.0
(21.8)
68 60.4 (21.7) 0.53 73 57.7
(20.8)
57 63.5 (21.4) 0.02 −3.99 (−10.17,
2.19)
0.21
WHO-5, (0–100) 73 63.2
(21.0)
64 65.4 (19.8) 0.44 67 59.4
(21.5)
54 62.4 (20.6) 0.48 −0.67 (−6.74, 5.39) 0.83
HADS-A, (0–21) 77 4.3 (3.3) 66 4.5 (3.9) 0.89 78 4.6 (4.0) 58 4.7 (3.9) 0.43 −0.25 (−1.28, 0.78) 0.63
HADS-D, (0–21) 77 4.7 (3.3) 66 4.7 (3.9) 0.88 78 5.4 (4.1) 58 5.1 (3.5) 0.57 0.15 (−0.83, 1.1) 0.76
Disease-specific Quality of Life measuresc
PAID-20, mean (SD) 68 21.6
(18.6)
64 25.4 (20.0) 0.04 62 21.4
(18.3)
48 22.3 (18.0) 0.76 2.56 (−1.95, 7.06) 0.27
PAID-20≥ 40 (%) 68 14 (20.6) 64 11 (17.2) 0.31 62 8 (12.9) 48 7 (14.6) 0.85 −0.34 (−1.22, 0.54) 0.45
NeuroQOL weighted (1–15)
Painful symptoms 75 4.0 (2.2) 65 4.1 (2.6) 0.97 73 4.2 (2.7) 58 4.2 (2.7) 0.89 0.06 (−0.77–0.88) 0.90
Reduced feeling 71 4.8 (3.7) 63 4.4 (3.3) 0.19 70 5.2 (3.3) 55 4.7 (3.3) 0.26 −0.03 (−1.06–0.99) 0.95
Diffuse sensorimotor
symptoms
70 5.8 (4.2) 64 5.5 (4.3) 0.29 71 5.7 (4.0) 54 5.4 (3.7) 0.12 0.23 (−0.78–1.24) 0.66
ADL restrictions 69 7.2 (4.2) 58 6.5 (3.7) 0.19 70 8.2 (4.4) 52 6.3 (4.0) 0.003 1.05 (−0.65–2.75) 0.23
Interpersonal burden 70 5.5 (3.9) 59 5.1 (4.0) 0.18 71 5.3 (3.5) 50 4.7 (3.6) 0.20 0.02 (−1.18–1.22) 0.97
Emotional distress 75 4.0 (2.2) 63 4.1 (2.6) 0.97 73 4.2 (2.7) 53 4.2 (2.7) 0.89 0.06 (−0.77–0.88) 0.90
Data are shown as mean ± SD for continuous variables and n (%) percent for categorical variables
aIn the current study we included all participants with at least one valid patient-reported outcome measure at baseline
bRegression coefficient for interaction between time and treatment group in linear mixed effects model for continuous outcome and generalized estimation
equations (GEE) for binary outcomes
cHigher scores on EQ-VAS, or WHO-5 reflect better perceived health, health state or psychological well-being. Higher scores on EQ-5D, HADS-anxiety or –
depression or PAID-20 reflect lower health-related quality of Life, more anxiety or depressive symptoms or more diabetes distress; Higher scores on the NeuroQOL
reflect greater impact of foot ulcers on quality of life
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we would not expect that different treatment outcomes
would cause improved PROMs in the telemedicine group
and the first proposed mechanism is thus unlikely to occur
[9]. However, there was some evidence that telemedicine
was perceived positively by participants. In general, patients
experienced that if TM functions as intended, it can be an
important additional tool [25]. Moreover, results from quali-
tative studies among healthcare personnel, conducted in
conjunction with this RCT, indicated that using the TM
intervention enhanced confidence among community
nurses, as they perceived improvement in their wound care
skills and facilitated more comprehensive DFU care [26–28].
The second proposed mechanism could thus have resulted
in improved PROMs in the telemedicine group. Neverthe-
less, positive experiences among healthcare personnel and
increased wound knowledge do not necessarily influence pa-
tients’ perception of health, well-being and QOL, which may
explain why we did not find any effects on PROMs.
Strengths and limitations
One strength of this study was the design; RCTs have been
recommended to improve the evidence-base for treating
DFUs in clinical practice and to facilitate changes in relevant
care pathways [29]. Another strength was the real-life con-
text as the study was performed in daily clinical practice at
three sites. It has been suggested that there is a need for
more research in TM interventions for well-defined patient
groups in order to increase study validity [30]; in this study
only participants with a DFU were included, not patients
with other types of ulcers or other foot problems. Finally, this
study used a broad range of PROMs, including disease-
specific measures, to reduce the problems with insensitive or
irrelevant outcome measures.
However, this study also has limitations. First, patients
with a diagnosed mental disorder or cognitive impair-
ment who might benefit most were excluded. More flex-
ible health services may be especially beneficial for
patients with more complex illness living in nursing
homes or having mental problems and those having dif-
ficulties traveling to a hospital. However, most of these
frail elderly patients were excluded from participation in
the current trial as they were unable to give informed
consent. Further, the sample size estimation was done
for the primary endpoint (ulcer healing time) and we
cannot rule out the possibility that we failed to detect
small positive or negative intervention effects because of
Type II error. Although it would be of interest to test if
the effect of the intervention on PROs differed between
patients with healed DFU and patients with remaining
DFU and/or amputations, the sample size of the current
study was too small to be able to detect such possible ef-
fect modifications. Participants in the study had a rela-
tive longstanding diabetes and most likely established
self-management routines. It is possible that it was too
optimistic to expect that a relative short telemedicine
intervention should affect patient reported outcomes. As
to user involvement, one patient was part of the research
team, however we could have invited a larger group of
patients as co-workers leading to a more systematic co-
production and an intervention perhaps better tailored
to patients’ needs [24, 31].
Conclusions
Telemedicine technology has emerged as a relevant al-
ternative to usual care for people with DFUs, facilitating
flexible healthcare services and close cooperation be-
tween levels of healthcare services [9]. The intervention
did not have a significant effect on DFU treatment out-
comes or PROMs; measures of health, well-being and
QOL were relatively stable from baseline to post-
intervention in both treatment groups. Although the
intervention did not yield short-term benefit for the par-
ticipants, it is notable that it was also was not associated
with worse outcomes. TM is as effective as face-to-face
care, while having greater reach. Future studies may re-
veal that it is possible to modify the telemedicine inter-
vention to more accurately fit settings and contexts in
order to generate both improved ulcer healing and
patient-reported outcomes.
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